- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- Centella asiatica product, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 1,989
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
- Interventions
- Diranersen, Diranersen-matching placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
- Conditions
- Frontotemporal Dementia, Alzheimer Disease
- Interventions
- Synchronous Rhythm Production, Solo Rhythm Production
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Amyloid, Amyloidosis, Spinal Stenosis, Transthyretin Amyloidosis, Primary Amyloidosis of Light Chain Type
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Alzheimer's Disease
- Interventions
- Meganatural-Az Grapeseed Extract, Placebo
- Drug
- Lead sponsor
- Hillel Grossman
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age Related Cognitive Decline, Alzheimer's Disease, Vascular Dementia, Endothelial Dysfunction, Executive Dysfunction
- Interventions
- Omega 3 PUFA, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Alzheimer's Disease, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alzheimer Disease, Dementia of Alzheimer Type
- Interventions
- PET/MR Imaging, 64Cu-FBP8
- Diagnostic Test · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- 3TC
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- San Antonio, Texas
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment
- Interventions
- Saline, Insulin detemir, Insulin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • Tacoma, Washington
- Conditions
- Healthy Volunteers
- Interventions
- BNC, Placebo
- Drug · Other
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 55 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- GSI-953
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Alzheimer's Disease
- Interventions
- Rivastigmine
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Alzheimer Dementia, Agitation,Psychomotor
- Interventions
- Electroconvulsive Therapy (ECT)
- Device
- Lead sponsor
- Brent Forester
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Belmont, Massachusetts • Grand Rapids, Michigan + 2 more
- Conditions
- Aging, Alzheimer Disease, Dementia
- Interventions
- Information, counseling and support
- Behavioral
- Lead sponsor
- Alzheimer's Association
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2031
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Cognitive Change
- Interventions
- High-Demand Photography, Moderate-Demand Photography, At-Home Engagement
- Behavioral
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Alzheimer Disease
- Interventions
- TRx0237 16 mg/day, Control, TRx0237 8 mg/day
- Drug
- Lead sponsor
- TauRx Therapeutics Ltd
- Industry
- Eligibility
- Up to 90 Years
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Multiple Sclerosis, Alzheimer's Disease
- Interventions
- [F-18]PBR06, [C-11]PBR28
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Tammie L. S. Benzinger, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer's Disease
- Interventions
- Oxaloacetate (OAA)
- Dietary Supplement
- Lead sponsor
- Russell Swerdlow, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Alzheimer's Disease
- Interventions
- VHB937, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
- Conditions
- Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland